12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Allovectin velimogene aliplasmid: Phase III ongoing

Vical disclosed in its 3Q12 earnings that an independent safety monitoring board completed its final review of safety data from the single-blind, U.S. Phase III AIMM trial of Allovectin and reported "no basis for any concern that there is undue risk...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >